Lower Risk MDS Per IPSS-R
1 clinical trials · Condition
◉ Watch Lower Risk MDS Per IPSS-R
| Record | Firm | Date |
|---|---|---|
| The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes (NCT05925504) | Institute of Hematology & Blood Diseases Hospital, China | 2023-07-01 |
Track Lower Risk MDS Per IPSS-R automatically
Every clearance here is in the API, with alerts when new ones post.